Skip to content
DataLookout
Menu

NCT07556549

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

StatusCompleted
PhaseNot specified
SponsorPfizer
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoints: details revised at 1 of 21 entries Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Aug 30, 2026 to Sep 24, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 4 of 9 entries
  2. Minor Primary and study completion pushed from Jun 30, 2026 to Aug 30, 2026v4
  3. Minor Start date: Apr 22, 2026 to May 18, 2026v3
  4. Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 20, 2026 to Apr 22, 2026
    • Secondary endpoints: details revised at 1 of 9 entries
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Age at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Smoking status (if available) at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Histology of patients at start of Lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Current cancer stage at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Brain metastases status at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of initial NSCLC diagnosis
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of a/mNSCLC diagnosis
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
ALK-positive diagnosis prior to Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Gene testing method and results prior to initiation of lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of brain metastases diagnosis prior to initiation of lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Presence of comorbidities at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Concomitant therapies at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of lorlatinib initiation
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Initial lorlatinib dose at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Dose adjustments when patients were prescribed with Lorlatinib Treatment
Timeframe: From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Gender at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Weight at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Height at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Body mass index (BMI) at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024

Secondary (9)

Time to Discontinuation (TTD) in 1 L lorlatinib patients
Last dose for Patients who are still on the Lorlatinib first line treatment
Treatment switching to other ALK TKls from Lorlatinib Treatment
1L lorlatinib resistance mechanism (if applicable)
Treatment switching to subsequence treatment from 1L Lorlatinib Treatment
Show 4 moreShow less
Medical Costs during lorlatinib treatment period
Brain metastases progression and date of patients receiving Lorlatinib treatment
Death (if applicable) of patients receiving Lorlatinib for the first-line treatment
The cumulative incidence rate of BM of patients receiving Lorlatinib for the first-line treatment

Arms and interventions

Lorlatinib in locally advanced/metastatic ALK-positive Non-Small Cell Lung Cancer Patients in China

Drugs: Lorlatinib

Sites

1 site in 1 country

  • PfizerBeijing, China